# Evaluating the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Carbavance™ (RPX2014/RPX7009) in Healthy Adult Subjects

> **NCT02073812** · PHASE1 · COMPLETED · sponsor: **Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)** · enrollment: 26 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** RPX7009 and RPX2014

## Key facts

- **NCT ID:** NCT02073812
- **Lead sponsor:** Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2018-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02073812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02073812, "Evaluating the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Carbavance™ (RPX2014/RPX7009) in Healthy Adult Subjects". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02073812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*